SCHEMBL30239072

SCHEMBL30239072

CC(C)(C)OC(=O)NCCn1cc(C(=O)O)c(Cc2ccccc2)n1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 1/20 0.44
SIGMAR1 Q99720 3/20 0.43
KMT2A Q03164 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
DRD2 P14416 1/20 0.41
AKT1 P31749 1/20 0.41
MALT1 Q9UDY8 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
CTSS P25774 2/20 0.39
ADORA3 P0DMS8 2/20 0.39
ADORA2A P29274 2/20 0.39
CTSL P07711 1/20 0.39
CTSB P07858 1/20 0.39
CTSK P43235 1/20 0.39
MAPT P10636 1/20 0.39
PPARA Q07869 2/20 0.38
PPARG P37231 1/20 0.38
BCHE P06276 1/20 0.38
SYK P43405 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24931118 0.89 CRHBP (0.45) IDO1SIGMAR1DRD2AKT1ADORA3
SCHEMBL24930987 0.82 CKS1B (0.47) IDO1KMT2AL3MBTL1DRD2AKT1
SCHEMBL21564331 0.80 ALDH1A1 (0.40) IDO1KMT2ADRD2MALT1ADORA3
SCHEMBL18765005 0.77 DGAT1 (0.40) IDO1SIGMAR1KMT2ADRD2MALT1
SCHEMBL30239588 0.76 CYP3A4 (0.47) IDO1SIGMAR1DRD2AKT1NPSR1
SCHEMBL24931213 0.76 JAK2 (0.42) SIGMAR1KMT2AL3MBTL1DRD2NPSR1
SCHEMBL31518543 0.75 MEN1 (0.38) KMT2ADRD2MALT1ADORA3ADORA2A
SCHEMBL30239158 0.74 MAPK1 (0.47) IDO1KMT2ANPSR1ADORA3ADORA2A
SCHEMBL17868978 0.73 TSHR (0.43) PPARAPPARG
SCHEMBL17274051 0.71 PDE10A (0.49) IDO1SIGMAR1KMT2ADRD2AKT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240376076-A1 INHIBITORS TARGETING UBIQUITIN SPECIFIC PROTEASE 7 (USP7) DANA-FARBER CANCER INSTITUTE, INC. 2024-11-14 US disclosed
CN-118401507-A Inhibitors targeting ubiquitin-specific protease 7 (USP 7) 丹娜法伯癌症研究院 2024-07-26 CN disclosed
EP-4373816-A1 INHIBITORS TARGETING UBIQUITIN SPECIFIC PROTEASE 7 (USP7) Dana-Farber Cancer Institute, Inc. (US) 2024-05-29 EP disclosed
WO-2023003973-A1 INHIBITORS TARGETING UBIQUITIN SPECIFIC PROTEASE 7 (USP7) DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-01-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240376076-A1 INHIBITORS TARGETING UBIQUITIN SPECIFIC PROTEASE 7 (USP7) USP7, USP47, USP2 IDO1 2454/4885SIGMAR1 4213/4885KMT2A 1939/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.